Clinical trial · Interventional
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
NCT00994123CI-TRIAL-00023593completedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erlotinib | Drug | Erlotinib | ALIAS |
| MM-121 | Drug | Seribantumab | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Phase 1: Dose-Escalation
- description
- Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
- interventionNames
- Drug: MM-121
- Drug: Erlotinib
- type
- ACTIVE_COMPARATOR
- label
- Phase 2: Control
- description
- Erlotinib (daily)
- interventionNames
- Drug: Erlotinib
- type
- EXPERIMENTAL
- label
- Phase 2: Treatment
- description
- MM-121 (QOW IV) and erlotinib (daily PO)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with locally advanced or metastatic non-small cell lung cancer. * Patients must be \>/= 18 years of age. * Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function. Exclusion Criteria: * Patients with a recent history (within 5 years) of another malignancy. * Patients who are pregnant or nursing. * Patients with clinically significant heart failure. * Patients with clinically significant eye or gastrointestinal abnormalities.
References
Publications (0)
Data not yet available
No reference posted for this study.